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Background  and objectives: India  has  the  highest  under-five  death toll globally,  approximately  20% of which  is attributed  to vaccine-preventable  diseases.
India’s  Universal  Immunization Programme  (UIP)  is  working both  to  increase immunization  coverage  and to  introduce new  vaccines.  Here,  we analyze
the  disease and financial burden alleviated  across  India’s  population (by wealth  quintile,  rural  or  urban  area,  and  state)  through increasing vaccination
rates  and  introducing  a rotavirus vaccine.
Methods: We  use IndiaSim,  a simulated  agent-based model  (ABM) of the  Indian population (including  socio-economic  characteristics  and  immunization
status)  and  the health  system to model  three interventions.  In  the  first  intervention, a rotavirus vaccine  is introduced  at  the  current  DPT3 immunization
coverage level  in India.  In  the second  intervention,  coverage of  three  doses  of rotavirus and DPT and one  dose of the  measles vaccine are  increased to
90%  randomly  across the  population.  In  the  third, we evaluate  an  increase  in immunization  coverage to 90% through  targeted  increases in  rural  and
urban  regions  (across  all  states) that  are below  that  level at  baseline. For  each intervention,  we evaluate  the  disease  and  financial burden  alleviated,  costs
incurred,  and the cost  per disability-adjusted  life-year  (DALY)  averted.
Results: Baseline  immunization coverage is low and has  a  large variance  across population segments and  regions.  Targeting  specific  regions can approx-
imately  equate  the rural  and  urban  immunization  rates. Introducing a rotavirus  vaccine at the  current  DPT3  level (intervention  one)  averts  34.7  (95%
uncertainty  range  [UR], 31.7–37.7) deaths and  $215,569  (95% UR,  $207,846–$223,292) out-of-pocket  (OOP)  expenditure  per 100,000  under-five children.
Increasing  all  immunization  rates to 90%  (intervention  two)  averts  an additional  22.1  (95% UR,  18.6–25.7) deaths  and $45,914  (95% UR, $37,909–$53,920)
OOP expenditure.  Scaling  up  immunization  by  targeting  regions  with  low  coverage (intervention three)  averts  a slightly higher number  of deaths and  OOP
expenditure.  The reduced  burden of  rotavirus diarrhea  is the  primary  driver of  the  estimated  health and  economic  benefits in all intervention  scenarios.
All three  interventions  are  cost  saving.
Conclusion:  Improving  immunization  coverage  and the  introduction of a  rotavirus vaccine significantly  alleviates disease  and financial burden in Indian
households.  Population  subgroups  or  regions  with low  existing  immunization  coverage  benefit  the  most from  the  intervention.  Increasing coverage by
targeting those  subgroups alleviates  the burden more than  simply increasing  coverage in the  population at  large.
©  2014  Published  by  Elsevier  Ltd.  This  is an open access article  under the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
India has the largest number of under-five deaths in the world
[1]. Vaccine-preventable diseases are a major contributor to the
burden, causing approximately 20% of under-five deaths in  South-
east Asia [2]. In 1985 India launched its Universal Immunization
Programme (UIP), which provides free vaccines for measles,
poliomyelitis, tuberculosis (BCG), hepatitis B, and diphtheria,
∗ Corresponding author at: Center for Disease Dynamics, Economics &  Policy,
Washington, DC, USA.
E-mail address: ramanan@cddep.org (R. Laxminarayan).
pertussis, tetanus (DPT). Despite these efforts, each year more than
50,000 children under the age of five die from measles in  India (44%
of global under-five measles deaths) [3].  India accounts for 56%
(2525) of global diphtheria cases, 18% (44,154) of pertussis cases,
and 23% (2404) of tetanus cases [4].  The UIP has yet to incorporate
existing vaccines against mumps, pneumococcal disease and
rotavirus.
In  the Global Immunization Vision and Strategy (GIVS) from
2005, the World Health Organization (WHO) and the United
Nations Children’s Fund (UNICEF) set a  goal for all countries to
achieve 90% national vaccination coverage and 80% coverage in
every district by 2010 [5].  The UIP has fallen short of these targets. In
2007 only 53.5% of children were fully vaccinated, and vaccination
http://dx.doi.org/10.1016/j.vaccine.2014.04.080
0264-410X/© 2014 Published by Elsevier Ltd.  This is  an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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coverage varied considerably across the country [6]. Immunization
coverage is predicted to have improved in recent years, but full
coverage remains below 70% in urban areas and below 60% in rural
areas [7].
Rotavirus vaccines were first introduced in  national immu-
nization programs in  2006 as a  key intervention to address
the burden of diarrheal disease. By January 2014, 53 coun-
tries had introduced rotavirus vaccines [8].  These vaccines have
the potential to significantly alleviate the disease and finan-
cial burden in India, where each year approximately 113,000
under-fives die from rotavirus (39% of diarrhea cases). Indi-
ans spend between $37.4 million and $66.8 million annually
on direct medical costs of rotavirus diarrhea hospitalizations
in children under five (457,000–884,000) and outpatient treat-
ment (2 million visits) [9].  In 2014 Indian regulators licensed the
Indian-made vaccine 116E following a successful Phase 3 trial
[10,11].
In this paper we  evaluate the health and financial effects
of interventions introducing a  rotavirus vaccine to the immu-
nization program and increasing the immunization coverage of
the DPT3 and measles vaccines. We build on IndiaSim [12],  a
simulated agent-based model (ABM) of the Indian population
and health system, and use household-level data on immu-
nization decisions. We simulate three intervention scenarios: (i)
the introduction of the rotavirus vaccine at the current DPT3
level; (ii) an increase in DPT3, measles, and rotavirus vac-
cination coverage to 90% (the GIVS target) randomly across
Indian households; and (iii), targeted state-level and rural–urban
implementation that increases coverage in sub-regions that
are below 90% immunization coverage in the baseline sce-
nario.
Our analysis does not include the benefits of poliomyelitis
immunization. India is polio-free and any changes in the coverage
level of the poliomyelitis vaccine will not yield additional health or
economic benefits. We also omit the BCG vaccine from the analysis:
the burden of miliary tuberculosis is  low [13],  and BCG coverage is
high in India [14].
2. Methods
2.1. Population sample
IndiaSim is populated with data from the District Level House-
hold Survey (DLHS-3, conducted during 2007–08) of India [6].
DLHS data are representative at the district level and cover
more than 720,000 households and 3.8 million individuals from
601 districts. The survey data include indicators on demo-
graphics, household socioeconomic status, household vaccination
choices of UIP vaccines, and other indicators of health-seeking
behavior. The simulations are based on a randomly selected sub-
set of 128,000 households comprising approximately 750,000
individuals.
2.2. Disease, vaccination, and treatment data
Table 1 presents the input data on the epidemiology, treatment,
and prevention of DPT, measles, and rotavirus. DPT and measles
incidences are calibrated using the case-fatality rates (CFR) and
the  GBD 2010 mortality rates [15]. Rotavirus incidence [16] is dis-
tributed across wealth quintiles according to  Rheingans et al. [17],
and CFR is calibrated to  that incidence and the mortality rate [18].
We do not include comorbidity of diseases because of a paucity of
data.
In the absence of data to parameterize a  demand function for
treatment of vaccine-preventable diseases, we assume that every-
one who  contracts a  vaccine-preventable disease seeks treatment.
We do  not model the effect of treatment on disease transmission.
We  assume that the baseline level of treatment utilization results
in the realized baseline incidence and mortality rates in the pop-
ulation. In  addition, we assume that the demand and supply of
treatment for individuals with disease is  equivalent across all simu-
lation scenarios. Treatment costs for DPT and measles are estimated
from the National Sample Survey (NSS) 60th round schedule 25
[19],  and treatment costs for rotavirus are from Tate et al. [9].  All
costs in the model are in 2013 US dollars.
Total routine immunization cost is the sum of costs for vac-
cines, personnel, vehicles and transportation, cold chain equipment
and maintenance, and program and other recurrent costs, includ-
ing planning, supervision, monitoring, and surveillance. The data
were collected from the Ministry of Health and Family Welfare
(MoHFW) by personal communication. We use the WHO  com-
prehensive multi-year planning (cMYP) for immunization tool to
analyze the data and assume that interventions are introduced in
2016. Costs include program as well as vaccine costs and are not
separable by vaccine type.
Baseline vaccination coverage rates are from 2011 estimates
[14].
2.3. Income data
The gross domestic product (GDP) per capita for India is from the
World Bank [20].  The distribution across wealth quintiles is  from
NSS expenditure data. The state-level GDP per capita is  from the
Indian government’s Press Information Bureau [21].
2.4. Model
IndiaSim is an iterative, stochastic ABM. The model comprises 67
regions, representing the urban and rural areas of 34 Indian states
and districts. Nagaland is  not included in  the model because it is
omitted from DLHS-3, and the urban area of Andaman and Nicobar
is  dropped because of a  low number of observations. Each region
comprises a set of representative households. A set of character-
istics describes each household (socioeconomic indicators) and its
individuals (age and sex). An iteration of a simulation represents a
day (the timestep of the model).
Individuals in the model are in one of several disease states:
they are healthy or they suffer from diphtheria, pertussis, tetanus,
measles, and/or rotavirus. They contract diseases based on a
stochastic function of their characteristics (age, sex, and wealth
quintile) and their immunization history. Those suffering from dis-
ease seek treatment at public or private facilities based on the
average treatment-seeking rates by income quintile in  the DLHS-
3 data. Births in the model are based on a  household-level probit
regression model that  is bounded to the state-level fertility rates
[12].  Deaths not related to  the five diseases in  the model are deter-
mined on the basis of WHO  life tables [22].
We assume that households that immunized previously born
children in  the baseline DLHS-3 data will immunize any children
born during the simulation with those vaccines. To increase the
urban and rural sub-region rates to 2011 estimates, we  select a
random set of households to also vaccinate. In the intervention sce-
narios, to  scale up the coverage rates, the model makes additional
households vaccination compliant. The method of selecting these
extra households varies across scenarios (e.g., random or targeted
by state and region).
The model was programmed in C++.
I. Megiddo et al. / Vaccine 32S (2014) A151–A161 A153
Table  1
Disease and intervention parameters.
Variable Base-case estimate Sensitivity range Source
Diphtheria
Incidence (per 100,000) Based on  [15] and CFR
<1  year 42.2 29.5–54.8
1–5 years 18.3 12.8–23.8
CFR  0.012 0.008–0.016 [37]
Cost of seeking treatment
Public facilities $0.35 $0.25–$0.46 [19]
Private facilities $0.37 $0.26–$0.49
Treatment cost
Public facilities $3.51 $2.45–$4.56 [19]
Private facilities $4.59 $3.21–$5.97
DPT3  vaccination relative risk reduction 0.955 0.921–0.989 [38]
Pertussis
Incidence (per 100,000) Based on  [15] and CFR
<1  year 2123.2 1486.3–2760.2
1–5 years 313.4 219.4–407.5
CFR  [39]
<1 year 0.037 0.026–0.048
1–4.9 years 0.010 0.007–0.013
Cost  of seeking treatment [19]
Public facilities $0.72 $0.50–$0.93
Private facilities $0.77 $0.54–$1.00
Treatment cost [19]
Public facilities $5.83 $4.08–$7.58
Private facilities $7.63 $5.34–$9.92
DPT3  vaccination relative risk reduction 0.840 0.680–1.00 [40]
Tetanus
Incidence (per 100,000) Based on  [15] and CFR
<1  year 637.1 446.0–828.2
1–5 years 3.2 2.2–4.1
CFR  [41]
<1 months 0.864 0.648–1.000
1 month–5 years 0.328 0.230–0.427
Cost  of seeking treatment [19]
Public facilities $0.55 $0.38–$0.71
Private facilities $0.58 $0.41–$0.76
Treatment cost [19]
Public facilities $3.54 $2.48–$4.60
Private facilities $4.63 $3.24–$6.02
DPT3  vaccination relative risk reduction 1.000 .990–1.00 [42]
DPT3 vaccination baseline coverage 76.8% Based on  [6,14]
Measles
Incidence (per 100,000) Based on  [15] and CFR
<1  year 4776.9 3343.9–6210.0
1–5 years 2723.3 1906.3–3540.3
CFR  0.015 0.011–0.020 [45]
Cost of seeking treatment
Public facilities $1.24 $0.87–$1.61 [19]
Private facilities $1.32 $0.92–$1.72
Treatment cost $5.92 $4.14–$7.69
Vaccination relative risk reduction 0.840 0.83–0.87 [43]
Vaccination baseline coverage 82.2% Based on  [6,14]
Rotavirus
Incidence (per child-year) Based on  [9,16,17]
<6 months quintile I 1.38 0.96–1.79
Quintile II 1.17 0.89–1.52
Quintile III 0.97 0.68–1.25
Quintile IV 0.76 0.53–0.98
Quintile V 0.50 0.35–0.65
6  months–1 year quintile I 2.08 1.46–2.70
Quintile II 1.81 1.27–2.35
Quintile III 1.53 1.07–1.99
Quintile IV 1.15 0.80–1.49
Quintile V 0.76 0.53–0.98
1–2  years quintile I 1.74 1.22–2.26
Quintile II 1.44 1.00–1.87
Quintile III 1.24 0.87–1.61
Quintile IV 0.94 0.66–1.22
Quintile V 0.59 0.42–0.77
2–5  years quintile I 1.11 0.78–1.44
Quintile II 0.94 0.66–1.23
Quintile III 0.78 0.55–1.01
Quintile IV 0.59 0.42–0.77
Quintile V 0.38 0.27–0.50
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Table 1 (Continued)
Variable Base-case estimate Sensitivity range Source
CFR 0.0009 0.00063–0.00117 Based on incidence and [18]
Outpatient cost of seeking treatment $0.36 $0.25–$0.46
Outpatient treatment cost $3.12 $2.18–$4.05 [9]
Inpatient cost of seeking treatment $3.70 $2.59–$4.81
Inpatient treatment cost $74.26 $51.99–$96.54
Vaccination relative risk reduction 0.56 0.420–0.700 [44]
Vaccination baseline coverage 0.00%
UIP cost per DPT3 child Based on cMYP and personal
communication with MoFWH
Baseline $22.50 $15.75–$29.25
Intervention one $27.00 $18.90–$35.10
Intervention two/three $23.50 $16.45–$30.55
2.5. Analysis
2.5.1. Simulated results from one year are analyzed in R
Analysis variables fall  into four categories, which consider the
intervention’s associated effect on disease burden, intervention
costs, cost-effectiveness, and financial impact. The effect on dis-
ease burden includes both deaths and disability-adjusted life years
(DALYs) averted (we discount at 3% and use uniform age-weights
that value any extra year of life equally). Cost-effectiveness is  mea-
sured by dollars per DALY averted incremental to the baseline
scenario. The financial impact measures follow Verguet et al. [23]
and include the out-of-pocket (OOP) expenditure averted from the
baseline scenario, which measures the savings of the population
that result from the intervention, and the money-metric value of
insurance, which measures the value of protection from expendi-
ture on disease treatment (including the costs of seeking care). The
money-metric value of insurance here differs slightly from Ver-
guet et al.’s analysis. Our analysis period is  one year as we study a
cross-section of the under-five population, while they study a birth
cohort, which is susceptible to disease over the first five years of
life. Given this, we  include only one year of disposable income in
the calculation as opposed to  five years. Additionally, we evalu-
ate the value of insurance of an intervention with respect to the
baseline by subtracting one from the other. We  analyze health and
financial burden alleviated across India by wealth quintile, state,
and rural versus urban areas.
2.6. Sensitivity analysis
To quantify the uncertainty of the model, we conduct a  100-
simulation Latin hypercube sampling (LHS) sensitivity analysis
over a plausible range of the input parameters (Table 1). For  each
disease, the parameters analyzed include the incidence, CFR, vac-
cine efficacy, vaccine cost, and treatment cost. Ninety-five percent
uncertainty ranges for our mean estimated outcomes are  calculated
on the basis of this sensitivity analysis and reported in parentheses.
3. Results
In the baseline, immunization coverage is 77% for DPT3, 82%
for measles, and there is no coverage for rotavirus. From DLHS-
3 data, we find that baseline coverage increases by  wealth for
DPT3 and measles. The rural-to-urban immunization coverage ratio
is 1.09 for DPT3 and 1.05 for measles (Fig. 1,  row 1). Baseline
DPT3 coverage is lowest in  Arunachal Pradesh and Uttar Pradesh
where 53% and 55% of under-fives are  vaccinated (Fig. 2,  column
1). Another nine states vaccinate less than 80% of their chil-
dren; all of them are relatively poor states, with the exception
of  Gujarat (77% coverage). Eight states have DPT3 coverage above
90%. Measles vaccination coverage in  six states is less than 80%;
as with DPT3, coverage is  lowest in Arunachal Pradesh (58%) and
Uttar Pradesh (60%). Twelve states are  above 90% coverage for
measles, and Himachal Pradesh and Maharashtra are above 95%
coverage.
Our interventions decrease the coverage disparity between
wealth quintiles, rural and urban populations, and states. Interven-
tion two reduces the urban-to-rural vaccine coverage ratio for all
three vaccines to 1.03 (Fig. 1, row 1), though a  total of  9 states
do not achieve 90% coverage for all vaccines, and measles cover-
age remains below 80% in  Arunachal Pradesh and Uttar Pradesh
(Fig. 2). Intervention three equates urban and rural coverage (i.e.,
the urban-to-rural vaccine coverage ratio is approximately 1)  and
makes coverage in each state at or above 90% for all three vac-
cines.
In the baseline scenario, India at large has 88.7 (95% uncertainty
range [UR], 85.1–92.4) rotavirus deaths per 100,000 under-fives;
the rate is  more than 60% higher in  rural areas than in  urban areas
(96.6 versus 59.8). Intervention one averts 34.7 (95% UR, 31.7–37.7)
deaths and 995 (95% UR, 910–1081) DALYs per 100,000 under-fives
per year, roughly 44,500 deaths and 1.28 million DALYs throughout
the country. The number of deaths averted per 100,000 under-fives
is  25.2 (95% UR, 19.9–30.5) in urban populations and 37.3 (95%
UR, 33.8–40.8) in rural populations (Fig. 1,  row  2). Intervention
two averts another 22.1 deaths (95% UR, 18.6–25.7) per 100,000
under-fives and 630 (95% UR, 522–737) DALYs per 100,000 for
all of the related diseases. Intervention three averts slightly more
deaths and DALYs than intervention two. Typically, the reduced
burden is highest for the poor and in rural areas (Fig. 1,  row 2); this
trend is  more pronounced in  intervention three than in interven-
tion two.
Fig.  3 (total deaths averted from the baseline across all under-
fives) and the first row of Fig. 4 (DALYs averted across all under-fives
in  one year) map  the disease burden alleviated in all interventions.
In all states with sufficient data, introducing the rotavirus vaccine
(intervention one) averts more than 15 rotavirus deaths and 450
DALYs per 100,000 under-fives, though the standard deviations are
high. The intervention averts more than 45 deaths per 100,000 in
Karnataka, Uttarakhand, Andhra Pradesh, Himachal Pradesh, West
Bengal, Jammu and Kashmir and Bihar and more than 1500 DALYs
per 100,000 in  Jammu  and Kashmir, Karnataka and Andhra Pradesh.
Intervention one costs almost $93 million per year for all of  India.
The total intervention costs are mapped in Fig. 4,  row  2. In interven-
tion one, the cost per 100,000 under-fives ranges from $26,127 (95%
UR, $16,996–$35,257) in  Arunachal Pradesh to $212,878 (95% UR,
$185,763–$239,994) in Delhi; the cost per 100,000 under-fives in
Uttar Pradesh is  low relative to other states (approximately 48,500),
but the state has the highest overall costs (approximately $14.1
million), taking into account the entire under-five population. The
urban-to-rural cost ratio is  1.17 (95% UR, 1.09–1.27) per 100,000
under fives.
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Fig. 1. Analysis by rural and urban populations per 100,000 under-fives in each.
Results are for 100 simulations. Confidence intervals around the mean are from the sensitivity analysis. OOP = out-of-pocket.
In interventions two (randomly increasing all three vaccines to
90% coverage) and three (increasing all three vaccines to  at least
90% coverage in each region), states with low coverage rates in
intervention one achieve the greatest additional reductions in bur-
den (Figs. 3 and 4,  row 1). For example, Uttar Pradesh has the
second lowest coverage in intervention one, and it averts an addi-
tional 427 (95% UR, 275–580) rotavirus-related DALYs per 100,000
under-fives per year in intervention two and 548 (95% UR, 372–724)
per 100,000 in intervention three. Approximately 665,000 DALYs
are averted for all five diseases in Uttar Pradesh in  intervention
three.
The intervention costs incremental to the baseline in  inter-
vention two for all five diseases are $137,926 (95% UR,
$120,787–$155,065) per 100,000 under-fives in  Uttar Pradesh
($41 million for its entire population) and above $30,000 in
all other states. In intervention three, the cost incremental
to  the baseline is  above $100,000 in nine states, includ-
ing Uttar Pradesh, where the cost is  $186,454 (95% UR,
$167,960–$204,948) per 100,000; the cost for all under-fives in
Uttar Pradesh is approximately $53 million (Fig. 4, row 2). The
urban-to-rural cost ratio is 0.88 (95% UR, 0.54–1.41) in inter-
vention two and 0.75 (95% UR, 0.47–1.17) in intervention three
(Fig.  2).
Most of the OOP expenditure averted results from the reduced
rotavirus burden (Figs. 2 and 5,  row 3): $232,354 (95% UR,
$224,029–$240,678) averted per 100,000 under-fives in interven-
tion one, with an additional $49,489 (95% UR, $40,861–$58,118)
and $56,295 (95% UR, $47,599–$64,991) averted in interventions
two and three, respectively. The OOP averted for DPT (approx-
imately 1800) and measles (approximately 5500) is highest in
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Fig. 2. Under-five immunization coverage.
Results are for 100 simulations. Rotavirus immunization is  not available in the baseline scenario, and therefore the map  is greyed out. Additionally, states with a  low sample
population are greyed out.
intervention three (Fig. 4, row 3?). The urban-to-rural ratio of
OOP expenditure averted decreases from intervention one through
intervention three (Fig.  1,  row 4; e.g., the rotavirus ratio decreases
from 0.70 to 0.48).
The interventions are cost saving in  all states that  have sufficient
data. If we exclude OOP expenditure averted and only consider
the intervention costs, the incremental dollars per DALY averted
in intervention one is  $70.89 (95% UR, 95% UR, $61.51–$80.28)
with respect to the baseline. For interventions two and three,
the incremental dollars per DALY averted are $30.47 (95% UR,
−$4.36–$65.28) and $36.97 (95% UR, $7.96–$65.97) with respect
to intervention one. Excluding OOP expenditure averted, the dol-
lars per DALY averted are below $110 in all states (with sufficient
sample size) in all interventions.
The value of intervening is highest for rotavirus. In inter-
vention one, the money-metric value of insurance for rotavirus
ranges from $521 (95% UR, $280–$761) per 100,000 under-fives
in Delhi to $6756 (95% UR, $6318–$7196) in  Bihar (Fig. 5).  It  is
highest in intervention three in Bihar (approximately $7500 per
100,000 under-fives) and Uttar Pradesh (approximately $5400 per
100,000). The values for DPT and measles are at or below $250 per
100,000 under-fives in  all states in all interventions. In all inter-
ventions, the money-metric value of insurance decreases as wealth
increases.
4. Discussion
In  this paper we  present an ABM analysis for introducing a
rotavirus vaccine to the UIP and increasing UIP coverage to the 90%
goal set in the GIVS. We  analyze the effects across the wealth dis-
tribution, the rural and urban population distribution, and states.
The results do not present the exact benefits and costs that would
be realized by implementing the intervention scenarios, but they
highlight the variation across population segments. The model is  a
useful tool  to understand which strategy and populations to target
when allocating scarce resources.
Immunization is one of the most cost-effective interventions for
improving health outcomes [24]. Even in  a  high-quality health sys-
tem, immunization policy addresses an important market failure:
individuals tend to  under-vaccinate, and government intervention
is needed to  fix that failure. Though India has succeeded in  elim-
inating polio, it has achieved less through routine immunization.
Targeted immunization campaigns may  be simpler to  implement
than routine immunization. For example, the pulse polio campaign
involved a  single-dose immunization. Routine vaccinations, how-
ever, may  require a  more complex immunization delivery schedule
if several doses are required.
UIP coverage remains low in India, especially in certain sectors
of the population. Targeting expansion in these subpopulations in
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Fig. 3. Total under-five deaths averted from baseline.
Results are for 100 simulations. DPT3 and measles vaccination coverage does not change in intervention one, and therefore the map is greyed out. States in which immunization
coverage is 90% or above in  the baseline are greyed out in intervention three. Additionally, states with a low sample population or a high standard deviation are greyed out.
intervention three averts a greater burden than the random vac-
cination distribution in  intervention two. This is partially because
coverage is slightly higher than 90% in intervention three (a few
states have higher-than-90% coverage in the baseline and maintain
that coverage rate in intervention three). However, the simulation
results also show that often the areas that suffer the highest dis-
ease burden and that  have the greatest potential marginal gains to
vaccination are the areas that currently under-vaccinate the most.
Although rural areas have lower rotavirus immunization cover-
age than urban areas in  intervention one, rural areas avert more
rotavirus deaths in  that scenario. Moreover, interventions tend to
have a greater financial benefit for those segments of the popula-
tion. Poor and rural areas avert more deaths and OOP expenditure
than urban areas.
Demand and supply both  contribute to  low immunization rates.
Lack of education contributes to low immunization demand. In a
UNICEF survey of vaccination coverage in  India, the most-cited rea-
sons for non-immunization included “did not feel the need,” “not
knowing about vaccines,” and “not knowing where to go for immu-
nization” [7]. Additionally, rural areas have poor access to  health
care facilities. Where facilities are available, they often suffer from
staffing issues and poor quality of service, which also decreases
health care demand [25].
The Indian immunization delivery system relies heavily on com-
munity health workers (CHWs) to mobilize and vaccinate the
rural population [26]. Strengthening CHW programs can increase
immunization coverage [26,27] and encourage age-appropriate
immunization [28]. Research suggests that providing incentives to
families can also improve vaccination rates [29].  However, effects
of these strategies have  been little studied.
Although India is not  currently reaching its target immunization
coverage with the UIP, it recognizes the potential of new vaccines.
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Fig. 4. Health and financial impact (totals by  state).
Results are for 100 simulations. States with a low  sample population or a  high standard deviation are greyed out. Values are in millions. OOP expenditure averted assumes
100%  demand for treatment. All interventions remain cost-effective if OOP expenditure averted is excluded. DALYs =  disability-adjusted life years; OOP = out-of-pocket.
It has introduced a new pentavalent vaccine in  a few states [30] and
plans to roll it out across the country in 2014–15. Given the resource
constraints, research into which vaccines alleviate the greatest
burden is important. A rotavirus vaccine is a  compelling choice.
Rotavirus puts a heavy burden on the Indian population, especially
on under-two year olds, and does not significantly decrease with
improvements in hygiene and sanitation [31].
Our analysis of a  rotavirus vaccine shows that its introduction
can significantly reduce rotavirus burden. We predict that introduc-
ing the vaccine at the DPT3 level will avert approximately 44,500
under-five rotavirus deaths per year in  India. Increasing rotavirus
immunization coverage to 90% in our model averts approximately
another 8500 and 9500 deaths in interventions two and three,
respectively; all three interventions are cost saving. Our results
for intervention one are similar to other cost-effectiveness mod-
els [32,33]. Our DPT3 coverage, which is  estimated for 2011, is
higher than that of Esposito et al. [33].  The similar result despite
the disparity in vaccination coverage is because of different model
assumptions. Our death rate is lower and our vaccine efficacy is
slightly higher. A  recent report by the International Vaccine Access
Center (IVAC) at Johns Hopkins Bloomberg School of Public Health
[34] uses a  baseline death rate much lower than ours (approx-
imately 54,000 versus 113,000) and estimates approximately
22,000 rotavirus deaths averted at 72% vaccination coverage. Their
cost averted differs significantly from our OOP averted, though in
addition to different model parameters they include components
we do not (e.g. lost productivity). Verguet et al. [23] estimate (with
DLH-3 vaccination rates) the OOP expenditure averted for a  1  mil-
lion birth cohort and the money-metric value of insurance for 1
million households. Their cohort averts $1.8 million OOP expendi-
ture over the first five years of life and the money-metric value of
insurance is $16,000 for 1 million households. We estimate that
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Fig. 5. Money-metric value of insurance per 100,000 under-fives.
Results are for 100 simulations. DPT3 and measles vaccination coverage does not change in intervention one, and therefore the map is greyed out. States in which immunization
coverage is 90% or above in the baseline are greyed out in intervention three. Additionally, states with a  low sample population or a  high standard deviation are greyed
out. Money-metric value of insurance =  the value of protection from the  risk of expenditure on  disease treatment (including the  costs of seeking care). It is  the amount the
population is willing to  pay to avoid that risk.
approximately $2.3 million OOP is averted and a money-metric
value of insurance of $23,500 summed over the wealth quintiles in
a cross-section 1 million population of under-fives. We  sum over
wealth quintiles for comparability with their study, though wealth
quintiles do not include an equal number of under-five year olds.
Our results are similar, but the comparison is  not exact due to  the
differing model populations and assumptions. The most significant
difference in model assumptions of the two analyses is the age
distribution of  the under-five population.
The cost-effectiveness results here are more optimistic than
other analyses [32,33] because of our assumption of 100% treat-
ment demand. If we do not consider OOP averted, we have a  lower
bound estimate of cost-effectiveness, and the interventions remain
very cost-effective by  WHO’s cost-effectiveness criteria [35]: the
cost per DALY averted is  less than India’s per capita GDP.
The regional detail in the model is  an additional reason for the
differences between our findings and past analyses. As discussed,
the marginal gains from immunization are often highest in  areas
that currently vaccinate the least. Introducing rotavirus according
to  DPT3 vaccination coverage (the same households) maintains that
trend.
A major challenge to  realizing the potential benefits described
here is the low investment in routine immunization [36]. In
2011–12 the MoHFW spent approximately $233 million on routine
immunization. Continuing the UIP at current coverage rates would
cost approximately $438 million in the intervention year (cMYP
and personal communication with MoHFW). The estimated cost for
the polio campaign during the intervention year is  approximately
$108 million. Under the model assumptions, introducing a  rotavirus
vaccine at DPT3 levels costs another approximately $93 million, or
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roughly a 17% increase on top of the total costs of the existing rou-
tine immunization and the polio campaign. Intervention three will
cost approximately $129 million more than would be spent in the
baseline ($53 million of which would be spent for Uttar Pradesh).
A significant increase in  immunization program funding is needed
both to introduce the new vaccines and to increase immunization
coverage in India.
The study is limited by the parameters we use.  Though our anal-
ysis focuses on the distribution across population subgroups, the
parameters do not capture all the covariates affecting these groups.
For example, we do not capture the state fixed effects in many of our
variables. We use the population distributions (by age, wealth, and
sex) to extrapolate the values for specific subgroups. Additionally,
we assume that the per-child UIP costs are distributed uniformly
across states. Despite not fully capturing all the factors affecting the
disease and expenditure distributions across the subpopulations,
we feel that this research is  a  step in  the right direction. Addition-
ally, we do not model the infectious disease dynamics, which means
we do not consider any additional benefits from herd immunity.
5. Conclusion
Introducing a rotavirus vaccine to  UIP and increasing UIP cov-
erage are cost-effective interventions that would greatly alleviate
the disease and financial burden of vaccine-preventable diseases
in India. The results presented here are useful for policy analysis,
given the paucity of data on the interventions’ effect size across dif-
ferent subsets of  the population: at the state level, in the rural and
urban populations, and across the wealth distribution. Additional
research is needed to  introduce an infectious disease model into
the  ABM used here and to  take into account the state fixed effects.
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